MOTS-c

If your provider determines you are not a candidate for any available treatment, any consultation fee paid will be refunded within 7–10 business days. You are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.

No. MOTS-c is studied as a mitochondrial-derived signaling peptide, not as a stimulant. Research connecting the body's own MOTS-c to exercise does not establish that injected MOTS-c recreates exercise, replaces training, or produces a stimulant-like effect.

MOTS-c was nominated through FDA’s 503A process for obesity and received a favorable recommendation from the Pharmacy Compounding Advisory Committee in July 2026. That is a regulatory review step, not an FDA approval, and FDA has not issued a final rule adding MOTS-c to the 503A Bulks List. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.

AnthologyRX does not present it that way. Weight and glucose effects reported in animal models do not establish a weight-loss result in people, and the FDA nomination for obesity is a regulatory fact rather than proof of efficacy. If weight loss is your primary goal, your provider can evaluate treatments with direct human evidence for that outcome instead.

That is a provider decision because controlled interaction data are limited. Your Assessment should include GLP-1 drugs, metformin, insulin, sulfonylureas, and any other medication that affects glucose or appetite. MOTS-c is being studied around metabolic signaling, so adding it to an existing plan without reviewing the whole plan would miss the point of clinician-guided care.

MOTS-c is a perfect example of why an interesting mechanism is not enough. Here, a licensed provider reviews whether the peptide belongs in your metabolic plan and a licensed US pharmacy compounds it to an individual prescription. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.^F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. AnthologyRX gives you a place to explore unusual biology without pretending unusual automatically means proven.